Project MD 960 - Diabetes and Insulin Resistance

“A treatment that simultaneously reduces insulin resistance, improves glycaemic control and decreases the risk of cardiovascular events would be a major therapeutic advance for type 2 diabetes”

Editorial NEJM 2007, 356: 2522–2524

Aus Bio has worked with an internationally recognised Melbourne-based cardiovascular and diabetes institute to add value to the diabetes program. A previously agreed contracted research program has now shown that the Aus Bio oral drug candidate(s) – in a peer-reviewed rodent model – both reduced hyperglycaemia and also showed evidence of anti-inflammatory activity.

The Aus Bio MD960/961 drug candidates have, as to date, the following characteristics based on preclinical results:

  • Hyperglycaemia normalised in two rodent models
  • Insulin sensitizer – non PPAR
    • Reduces insulin levels in mouse model (db/db)
  • Inhibition of PTP’ase, not PTP1B but LAR
  • Induction of nitric oxide
    • Positive vascular effects, important to FDA
    • Reduces BP (in vivo rabbit model)
  • Anti-inflammatory activity
  • Orally bioavailable, good safety profile